EUVIMEDEUVIMED entdecken
Crossref

crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer

Yutian Zou, Anli Yang, Bo Chen, Xinpei Deng, Jindong Xie, Danian Dai, Jinhui Zhang, Hailin Tang, Tao Wu, Zhigang Zhou, Xiaoming Xie, Jin Wang

Drug Resistance Updates · 2024-11 · 77 · 101126

DOI: 10.1016/j.drup.2024.101126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-11. Verfasst von Yutian Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Ferroptosis, Breast Neoplasms, Ubiquitination, Trastuzumab. Die Arbeit wurde bisher 117-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Guangzhou Municipal Science and Technology Program key projects, National Postdoctoral Program for Innovative Talents, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: With the wide application of trastuzumab deruxtecan (T-DXd), the survival of HER2-low breast cancer patients is dramatically improved. However, resistance to T-DXd still exists in a subset of patients, and the molecular mechanism remains unclear. METHODS: An in vivo shRNA lentiviral library functional screening was performed to identify potential circular RNA (crRNA) that mediates T-DXd resistance. RNA pull-down, mass spectrometry, RNA immunoprecipitation, and co-immunoprecipitation assays were conducted to investigate the molecular mechanism. Ferroptosis was detected using C11-BODIPY, Liperfluo, FerroOrange staining, glutathione quantification, malondialdehyde quantification, and transmission electron microscopy. Molecular docking, virtual screening, and patient-derived xenograft (PDX) models were used to validate therapeutic agents. RESULTS: VDAC3-derived crRNA (crVDAC3) ranked first in functional shRNA library screening. Knockdown of crVDAC3 increased the sensitivity of HER2-low breast cancer cells to T-DXd treatment. Further mechanistic research revealed that crVDAC3 specifically binds to HSPB1 protein and inhibits its ubiquitination degradation, leading to intracellular accumulation and increased levels of HSPB1 protein. Notably, suppression of crVDAC3 dramatically increases excessive ROS levels and labile iron pool accumulation. Inhibition of crVDAC3 induces ferroptosis in breast cancer cells by reducing HSPB1 expression, thereby mediating T-DXd resistance. Through virtual screening and experimental validation, we identified that paritaprevir could effectively bind to crVDAC3 and prevent its interaction with HSPB1 protein, thereby increasing ubiquitination degradation of HSPB1 protein to overcome T-DXd resistance. Finally, we validated the enhanced therapeutic efficacy of T-DXd by paritaprevir in a HER2-low PDX model. CONCLUSION: This finding reveals the molecular mechanisms underlying T-DXd resistance in HER2-low breast cancer. Our study provides a new strategy to overcome T-DXd resistance by inhibiting the interaction between crVDAC3 and HSPB1 protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisBreast NeoplasmsUbiquitinationTrastuzumabDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesHumansFemaleAnimalsMiceRNA, CircularHSP27 Heat-Shock ProteinsMolecular ChaperonesCell Line, TumorXenograft Model Antitumor AssaysMolecular Docking SimulationHeat-Shock Proteins

Stichwörter der Autor:innen

Breast cancerCircular RNADrug resistanceFerroptosisHER2-lowTrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesRNA, CircularHSP27 Heat-Shock ProteinsMolecular ChaperonesHeat-Shock ProteinsHSPB1 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
  • Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), Changde, China. Electronic address: radiotherapy_wutao@qq.com.
  • Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), Changde, China. Electronic address: nhzhouzhigang@sina.com.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: xiexm@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: wangjin1@sysucc.org.cn.

Förderung

  • Guangzhou Municipal Science and Technology Program key projects
  • National Postdoctoral Program for Innovative Talents
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangdong Provincial Applied Science and Technology Research and Development Program

Zitieren

APA

Zou, Y., Yang, A., Chen, B., Deng, X., Xie, J., Dai, D., Zhang, J., Tang, H., Wu, T., Zhou, Z., Xie, X., & Wang, J. (2024). crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resistance Updates, 77, 101126. https://doi.org/10.1016/j.drup.2024.101126

Vancouver

Zou Y, Yang A, Chen B, Deng X, Xie J, Dai D, et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resistance Updates. 2024;77:101126. doi:10.1016/j.drup.2024.101126

BibTeX
@article{Zou2024,
  author = {Zou, Yutian and Yang, Anli and Chen, Bo and Deng, Xinpei and Xie, Jindong and Dai, Danian and Zhang, Jinhui and Tang, Hailin and Wu, Tao and Zhou, Zhigang and Xie, Xiaoming and Wang, Jin},
  title = {crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {77},
  pages = {101126},
  doi = {10.1016/j.drup.2024.101126}
}
Kostenlos starten →